Rasche, Mareike
Zimmermann, Martin
Borschel, Lisa
Bourquin, Jean-Pierre
Dworzak, Michael
Klingebiel, Thomas
Lehrnbecher, Thomas
Creutzig, Ursula
Klusmann, Jan-Henning http://orcid.org/0000-0002-1070-0727
Reinhardt, Dirk
Article History
Received: 22 November 2017
Revised: 18 January 2018
Accepted: 24 January 2018
First Online: 22 February 2018
Compliance with ethical standards
:
: J.-P.B. has consulting or advisory roles for Amgen and Roche. T.K. has consulting or advisory roles for Loxo and Novartis. T.L. receives honoraria from Gilead, Merk Sharp & Dome, Astella, Basilea, and has consulting or advisory roles and participates in speakers’ bureaus, including travel accommodation and other expenses from Gilead, Merk Sharp & Dome, Astella. T.L. receives research funding from Gilead. D.R. has consulting or advisory roles for Roche, Celgene, Hexal, Pfizer, Novartis, Boehringer and receives research funding from Celgene. D.R. received travel, accommodation or other expenses from Jazz Pharmaceuticals and Griffols. The remaining authors declare that they have no conflict of interest.